<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00025051</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068840</org_study_id>
    <secondary_id>CPMC-U19-CA81888-01-UV</secondary_id>
    <secondary_id>CPMC-IRB-9923</secondary_id>
    <secondary_id>NCI-P01-0191</secondary_id>
    <nct_id>NCT00025051</nct_id>
  </id_info>
  <brief_title>Celecoxib in Preventing Skin Cancer</brief_title>
  <official_title>A Phase II, Double-Blind, Placebo-Controlled Clinical Trial To Assess Celecoxib As A Chemopreventive Agent Inhibiting UV-Induced Erythema And Cutaneous Carcinogenesis As Assessed Through Surrogate Biological Markers In Biopsied Skin After Exposure Of Skin In Normal Volunteers Ages 20-60 Years Old With Fitzpatrick Type I, II, III And IV Skin To UV-Radiation From Artificial Light Sources</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Celecoxib may be effective in preventing skin cancer by decreasing redness caused&#xD;
      by exposure to ultraviolet light and changing potential skin cancer biomarkers. It is not yet&#xD;
      known whether celecoxib is more effective than a placebo in preventing skin cancer.&#xD;
&#xD;
      PURPOSE: Randomized phase II trial to study the effectiveness of celecoxib in preventing skin&#xD;
      cancer in participants exposed to ultraviolet light.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine whether celecoxib decreases ultraviolet(UV)-induced erythema and affects&#xD;
           surrogate biomarkers of potential neoplastic change in participants with Fitzpatrick&#xD;
           type I-IV skin exposed to UV light.&#xD;
&#xD;
      OUTLINE: This is a randomized, double-blind, placebo-controlled study. Participants are&#xD;
      randomized to one of two treatment arms.&#xD;
&#xD;
        -  Arm I: Participants receive oral celecoxib twice daily for approximately 120 days.&#xD;
&#xD;
        -  Arm II: Participants receive oral placebo twice daily for approximately 120 days.&#xD;
&#xD;
      Skin biopsies of UV-exposed sites are evaluated.&#xD;
&#xD;
      Participants are followed for up to 5 weeks post-treatment.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 36 participants (18 per arm) will be accrued for this study&#xD;
      within 8 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment type="Actual">0</enrollment>
  <condition>Non-melanomatous Skin Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>anti-cytokine therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>antiangiogenesis therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biological therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cancer prevention intervention</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>chemoprevention of cancer</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>growth factor antagonist therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Fitzpatrick type I-IV skin&#xD;
&#xD;
          -  No history of photosensitivity (e.g., systemic or discoid lupus erythematosus,&#xD;
             polymorphous light eruption, or photocontact dermatitis)&#xD;
&#xD;
          -  No history of abnormal tanning responses or other unusual reactions to natural or&#xD;
             artificial light sources&#xD;
&#xD;
          -  Willing to wear sun-protective clothing and SPF 15-49 sunscreen&#xD;
&#xD;
          -  Willing and able to restrict the frequency of high ultraviolet-exposure activities&#xD;
             (e.g., exposure to sunlight, tanning boxes, or other artificial light sources)&#xD;
&#xD;
          -  No history of keloid formation&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  20 to 60&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC ≥ 3,500/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 12.0 g/dL&#xD;
&#xD;
          -  No bleeding disorder&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin ≤ 20% above upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT ≤ 20% above ULN&#xD;
&#xD;
          -  No chronic or acute hepatic disease&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine ≤ 20% above ULN&#xD;
&#xD;
          -  No chronic or acute renal disease&#xD;
&#xD;
        Gastrointestinal:&#xD;
&#xD;
          -  No active gastrointestinal disease (e.g., inflammatory bowel disease)&#xD;
&#xD;
          -  No pancreatic disease&#xD;
&#xD;
          -  No esophageal, gastric, pyloric channel, or duodenal ulceration&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No invasive cancer except nonmelanoma skin cancer cured by excision or stage I&#xD;
             cervical cancer&#xD;
&#xD;
          -  No hypersensitivity or adverse reactions to NSAIDs, salicylates, cyclo-oxygenase-2&#xD;
             (COX-2) inhibitors, or sulfonamides&#xD;
&#xD;
          -  No condition that would preclude the use of NSAIDs&#xD;
&#xD;
          -  No clinically significant laboratory abnormalities&#xD;
&#xD;
          -  No medical or psychosocial condition that would preclude study participation&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile participants must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No concurrent chemo-immunotherapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Biologic therapy&#xD;
&#xD;
          -  At least 1 year since prior chemotherapy, including topical fluorouracil&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least 2 weeks since prior topical glucocorticoids&#xD;
&#xD;
          -  At least 30 days since prior systemic corticosteroids&#xD;
&#xD;
          -  No concurrent systemic glucocorticoids (inhaled corticosteroids allowed)&#xD;
&#xD;
          -  No concurrent topical corticosteroids&#xD;
&#xD;
          -  No concurrent hormonal therapy&#xD;
&#xD;
          -  Hormone replacement (e.g., estrogen or thyroid replacement) allowed&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 14 days since prior aspirin (&gt; 100 mg/day) or other non-steroidal&#xD;
             anti-inflammatory drugs (NSAIDs) taken at least 3 times per week&#xD;
&#xD;
          -  At least 2 weeks since prior topical alpha hydroxy acids (e.g., glycolic acid or&#xD;
             lactic acid)&#xD;
&#xD;
          -  At least 6 months since prior oral retinoids (3 months for topical retinoids to the&#xD;
             face)&#xD;
&#xD;
          -  At least 30 days since prior treatment for esophageal, gastric, pyloric channel, or&#xD;
             duodenal ulceration&#xD;
&#xD;
          -  At least 30 days since prior investigational medication&#xD;
&#xD;
          -  No other concurrent investigational medication&#xD;
&#xD;
          -  No concurrent topical vitamin A derivatives and/or alpha hydroxy acids&#xD;
&#xD;
          -  No concurrent immunosuppressive drugs&#xD;
&#xD;
          -  No concurrent topical medication to the skin, including prescription and&#xD;
             over-the-counter preparations (moisturizers and emollients allowed)&#xD;
&#xD;
          -  No concurrent lithium, fluconazole, or warfarin&#xD;
&#xD;
          -  No concurrent chronic NSAIDs (&gt; 3 times per week for &gt; 2 consecutive weeks per year)&#xD;
&#xD;
          -  Concurrent cardioprotective doses of aspirin (≤ 100 mg/day) allowed&#xD;
&#xD;
          -  Concurrent acetaminophen allowed&#xD;
&#xD;
          -  No concurrent green tea consumption of &gt; 2 cups per day&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David R. Bickers, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Herbert Irving Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center at Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2006</verification_date>
  <study_first_submitted>October 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>March 21, 2013</last_update_submitted>
  <last_update_submitted_qc>March 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 22, 2013</last_update_posted>
  <keyword>basal cell carcinoma of the skin</keyword>
  <keyword>squamous cell carcinoma of the skin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Skin Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Mitogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

